Active — Not RecruitingNot Applicable

Predicting High-Flow Nasal Cannula Failure Using an Electrical Impedance Tomography-Derived Index: A Multicenter Study

China90 participantsStarted 2023-12-01

Plain-language summary

High-Flow Nasal Cannula (HFNC) therapy is widely used to treat acute respiratory failure. However, predicting therapy failure remains challenging as conventional indices rely on intermittent measurements and cannot provide continuous, objective monitoring. Electrical Impedance Tomography (EIT) enables non-invasive, real-time assessment of regional lung ventilation. This study evaluated whether an EIT-derived Flow Index (FI) could predict HFNC therapy failure within 48 hours.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Acute respiratory failure requiring HFNC * Stable hemodynamics * FiO₂ ≤0.6 Exclusion Criteria: * Neuromuscular disease affecting spontaneous breathing * Pregnancy * Contraindications to EIT * Poor EIT signal quality

What they're measuring

HFNC Failure Rate

Timeframe: Within 48 hours of HFNC initiation

Trial details

NCT IDNCT07366541

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Acute Respiratory Failure trials